Connection

Co-Authors

This is a "connection" page, showing publications co-authored by NAOTO T UENO and AYSEGUL A SAHIN.
Connection Strength

1.180
  1. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024 Aug 21; 43(1):236.
    View in: PubMed
    Score: 0.246
  2. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021 Sep; 189(2):455-461.
    View in: PubMed
    Score: 0.197
  3. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer. 2018 01; 89:64-71.
    View in: PubMed
    Score: 0.154
  4. Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Br J Cancer. 2017 Feb 14; 116(4):509-514.
    View in: PubMed
    Score: 0.145
  5. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  6. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  7. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  8. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer. 2019; 10(12):2635-2642.
    View in: PubMed
    Score: 0.043
  9. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
    View in: PubMed
    Score: 0.040
  10. Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. Mol Ther Oncolytics. 2017 Sep 15; 6:1-9.
    View in: PubMed
    Score: 0.037
  11. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
    View in: PubMed
    Score: 0.036
  12. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12780-12785.
    View in: PubMed
    Score: 0.036
  13. Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis. 2016 Dec; 37(12):1180-1189.
    View in: PubMed
    Score: 0.035
  14. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
    View in: PubMed
    Score: 0.033
  15. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 2001 Dec; 7(12):4008-12.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.